MarketCap
Facebook
X
TelegramQuarterly report 2025-Q4
added 02-12-2026
Acasti Pharma Cash and Cash Equivalents 2011-2026 | ACST
Annual Cash and Cash Equivalents Acasti Pharma
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 22.1 M | 23 M | 27.9 M | 30.3 M | 50.9 M | 14.2 M | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 50.9 M | 14.2 M | 28.1 M |
Quarterly Cash and Cash Equivalents Acasti Pharma
| 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 18.7 M | 16.9 M | 20 M | 22.1 M | 836 K | 1.02 M | 3.04 M | 23 M | 2.06 M | 10.6 M | 5.41 M | 27.9 M | 26.2 M | 34.9 M | 38.4 M | 30.3 M | 33 M | 36.9 M | 41 M | 50.9 M | 26.5 M | 11.6 M | 12.1 M | 14.2 M | 16.9 M | 2.62 M | 1.11 M | 16.9 M | 6.42 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 50.9 M | 836 K | 19 M |
Cash and Cash Equivalents of other stocks in the Biotechnology industry
| Issuer | Cash and Cash Equivalents | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
158 M | - | 2.43 % | $ 254 M |  Germany |
 |
Grifols, S.A.
GRFS
|
980 M | $ 7.68 | - | $ 6.83 B |  Spain |
 |
Altimmune
ALT
|
43.8 M | $ 3.47 | 3.74 % | $ 306 M |  USA |
 |
Amgen
AMGN
|
9.13 B | - | - | $ 188 B | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
170 M | - | - | $ 915 M | USA |
 |
I-Mab
IMAB
|
4.76 B | - | - | $ 866 M |  China |
 |
Genfit SA
GNFT
|
81.8 M | - | 2.54 % | $ 160 B |  France |
 |
Heron Therapeutics
HRTX
|
28.6 M | - | - | $ 130 M | USA |
 |
Biophytis SA
BPTS
|
5.57 M | - | -13.47 % | $ 169 M | France |
 |
Ascendis Pharma A/S
ASND
|
616 M | $ 218.0 | -1.75 % | $ 5 B |  Danmark |
 |
Midatech Pharma plc
MTP
|
1.67 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Applied Genetic Technologies Corporation
AGTC
|
46.4 M | - | - | $ 26.5 M | USA |
 |
ARCA biopharma
ABIO
|
61.6 M | - | 1052.0 % | $ 415 M | USA |
 |
Aeterna Zentaris
AEZS
|
16.4 M | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
345 K | - | -10.17 % | $ 12.2 K | USA |
 |
Acorda Therapeutics
ACOR
|
30 M | - | -24.86 % | $ 820 K | USA |
 |
Albireo Pharma
ALBO
|
248 M | - | -0.23 % | $ 916 M | USA |
 |
Aileron Therapeutics
ALRN
|
12.9 M | - | 10.36 % | $ 9.8 M | USA |
 |
Incyte Corporation
INCY
|
3.1 B | $ 90.75 | -0.03 % | $ 17.7 B | USA |
 |
Inovio Pharmaceuticals
INO
|
14.3 M | $ 1.57 | -0.63 % | $ 34.8 M | USA |
 |
Avenue Therapeutics
ATXI
|
2.59 M | - | -52.27 % | $ 4.45 M | USA |
 |
Adverum Biotechnologies
ADVM
|
60.7 M | - | - | $ 86.2 M | USA |
 |
Acer Therapeutics
ACER
|
2.33 M | - | 2.71 % | $ 14 M | USA |
 |
Advaxis
ADXS
|
4.88 M | - | -9.65 % | $ 45.9 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
2.41 M | - | - | $ 7.46 M |  Israel |
 |
Cullinan Management
CGEM
|
88.3 M | $ 12.91 | 1.33 % | $ 778 M | USA |
 |
Atreca
BCEL
|
30.8 M | - | -11.76 % | $ 5.79 M | USA |
 |
BioDelivery Sciences International
BDSI
|
112 M | - | -4.8 % | $ 255 M | USA |
 |
BeiGene, Ltd.
BGNE
|
4.55 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Inventiva S.A.
IVA
|
96.6 M | $ 6.11 | 5.71 % | $ 138 M | France |
 |
Calithera Biosciences
CALA
|
59.5 M | - | -10.95 % | $ 876 K | USA |
 |
Cara Therapeutics
CARA
|
51.8 M | - | -3.03 % | $ 260 M | USA |
 |
ChemoCentryx
CCXI
|
50 M | - | - | $ 3.74 B | USA |
 |
Bellerophon Therapeutics
BLPH
|
6.92 M | - | -74.18 % | $ 955 K | USA |
 |
Checkpoint Therapeutics
CKPT
|
6.6 M | - | - | $ 169 M | USA |
 |
Clovis Oncology
CLVS
|
143 M | - | -7.23 % | $ 13 M | USA |
 |
KalVista Pharmaceuticals
KALV
|
132 M | $ 16.73 | -1.59 % | $ 831 M | Britain |
 |
Aeglea BioTherapeutics
AGLE
|
85.7 M | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
811 M | - | - | $ 867 M | Germany |
 |
Denali Therapeutics
DNLI
|
175 M | $ 21.04 | 4.31 % | $ 3.46 B | USA |
 |
Kamada Ltd.
KMDA
|
75.5 M | $ 8.27 | 0.24 % | $ 260 M | Israel |
 |
Karyopharm Therapeutics
KPTI
|
62.5 M | $ 6.93 | -9.17 % | $ 845 K | USA |
 |
Keros Therapeutics
KROS
|
287 M | $ 11.17 | 1.92 % | $ 416 M | USA |
 |
Akero Therapeutics
AKRO
|
340 M | - | - | $ 3.67 B | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
26.3 M | $ 4.3 | 1.37 % | $ 714 M | Canada |
 |
Akouos
AKUS
|
122 M | - | 0.23 % | $ 488 M | USA |